Get actionable insights on how COVID-19 is impacting your business sector.Enquire now
This market research report on the global premature ejaculation therapeutics market offers analysis on market size & forecast, market share, industry trends, growth drivers, and vendor analysis. The market study also includes insights on segmentation by drug class (SSRIs, PDE5 inhibitors, anesthetic agents, and others), by ROA (oral therapeutics and topical therapeutics), and by geography (North America, Europe, APAC, Latin America, and MEA).
Premature Ejaculation Therapeutics Market - Overview
The increasing incidences of emotional and mental stress and other male sexual disorders, especially erectile dysfunction (ED) is fueling the growth of the global premature ejaculation therapeutics market. PE is the most prevalent sexual disorder among men across the globe. In recent years, the progress in medical research has increased the knowledge about several diseases to an in-depth level, thereby disclosing new target sites for drug treatment in the global market. The first oral drug was approved in 2009, and there are quite a few numbers of the drug under investigation for treating PE in the worldwide market. With the presence of a single approved oral premature ejaculation drug, the market regionally and globally is dominated by off-label drugs, generic versions of patent expired drugs and OTC formulations. The growing demand for various off-label and generic therapeutics will augment the growth of the global market over the next few years. The introduction of SSRIs and topical formulations is expected to revolutionize the market. Several vendors are offering off-label drugs that belong to different drug classes such as SSRIs, PDE5 inhibitors, and OTC topical creams/sprays for treating this disease. The increasing disease awareness, growing patient willingness to seek pharmaceutical therapy assistance for disease management, and the increasing presence of favorable guidelines that recommended the use of drugs as first-line therapy are the some of the major factors attributing to the growth of the global market. The increasing use of oral agents due to ease of use and absence of systemic side-effects will drive sales in the global premature ejaculation therapeutics market.
The entry of new vendors is leading to high capital investment for R&D activities and the manufacturing of new prescription drugs in the global market. The increasing awareness and focus on sexual wellness will create lucrative opportunities for leading vendors operating in the market. The global premature ejaculation therapeutics market is estimated to reach revenues of approximately $3 billion by 2024, growing at a CAGR of around 9% during 2018-2024.
Premature Ejaculation Therapeutics Market – Dynamics
The growing emphasis on the clinical progress of love hormones receptor antagonists is driving the growth of the global premature ejaculation therapeutics market. The existence of unmet demand is encouraging the progress of scientific research to understand better disease pathophysiology as certain novel drug targets and to innovate novel molecules with better efficacy and safety in the global market. The growing focus on the development of new molecules, which can inhibit the CNS neurotransmitter, oxytocin is also known as the love hormone will lead to the launch of new products in the market. Recent scientific researches result in the discovery of the involvement of oxytocin in central and peripheral oxytocinergic neurotransmission in the ejaculatory process. Several clinical trials and pre-clinical studies suggest the potential for highly selective oxytocin receptor antagonists in the treatment of PE. The pipeline studies of these drugs with oxytocin receptor antagonists will create the high potential to gain regulatory approval and access for the treatment in the global premature ejaculation therapeutics market during the forecast period.
Premature Ejaculation Therapeutics Market – Segmentation
This market research report includes a detailed segmentation of the market by drug class, ROA, and geography.
Premature Ejaculation Therapeutics Market – By Drug Class
The efficacy and safety of SSRIs will boost the demand for these drugs in the global premature ejaculation therapeutics market
The global premature ejaculation therapeutics market by drug class is segmented into SSRIs, PDE5 inhibitors, anesthetic agents, and others. SSRIs segment dominated more than 1/3rd of the total market share in 2018, growing at a CAGR of more than 8% during the forecast period. SSRIs is the most common type of drug for premature ejaculation treatment, and the introduction of Priligy (dapoxetine), which gained regulatory approval in 2009 is fueling the growth of this segment in the global market. According to multiple pre-clinical and clinical studies, alternation of the physiological activity of these 5-HT receptors with the antidepressant selective serotonin reuptake inhibitors (SSRIs) results in delayed ejaculation. The multiple evidence-based clinical trials that offer satisfactory efficacy and safety of SSRIs is contributing to the sale of these therapeutics in the global market. A recent survey conducted in the US indicated that 71% of the urologists prescribed an SSRI as the initial management of PE. The increasing pattern of healthcare professionals' recommendation of SSRIs will contribute to the growth of the global premature ejaculation therapeutics market.
Some of the common brand names of PDE5 inhibitors that are available in the global market include Cialis, Viagra, and Levitra. The plethora of unlicensed formulations, comprising anesthetic drugs and anesthetic agents will lead to an increase in clinical trials in the market. The other drugs that are available in the global premature ejaculation therapeutics market are opioid-based analgesics, alpha-blockers, beta-adrenergic blockers, TCAs, and SNRIs.
Premature Ejaculation Therapeutics Market – By ROA
Minimal risk of systemic adverse effects of topical drugs will boost sales in the global premature ejaculation therapeutics market
The ROA segment in the global premature ejaculation therapeutics market is classified into oral therapeutics and topical therapeutics. Topical therapeutics is the fastest growing segment in the global market, at a CAGR of over 10% during the forecast period. The continual approval for new topical OTC formulations, rise in product uptake of existing products due to increase in disease awareness, and interest of couples for sexual wellbeing are some of the factors attributing to the growth of this segment in the global market. The different varieties of topical formulations available in the global market include formulations include creams, gels, sprays, powders, emulsion, solutions, and ointments. Most of the topical PE drug formulations are amide anesthetics, which comprise lidocaine, benzocaine or a combination of lidocaine and prilocaine. The increasing availability of these products as OTC drugs and can be purchased without physicians' prescription is driving the demand for these products in the global market. These drugs offer improved ease of use and are associated with minimal/no systemic adverse events thereby, boosting sales in the global premature ejaculation therapeutics market.
The presence of a wide range of drugs recommended by physicians for the management of this condition is contributing to the demand for oral therapeutics in the global market. The daily dose oral therapies can exhibit improved and enhanced efficacy over topical therapies for treating PE. Some of the leading off-label oral formulation brands available in the global premature ejaculation therapeutics market are Viagra, Cialis, Zoloft, Paxil, Prozac, Levitra, and Lexapro.
Premature Ejaculation Therapeutics Market – By Geography
The launch of a large variety of OTC drugs across North America will contribute to the growth of the global premature ejaculation therapeutics market
The global premature ejaculation therapeutics market by geography is categorized into North America, Europe, APAC, Latin America, and MEA. North America occupied the largest market share in 2018, growing at a CAGR of around 9% during the forecast period. The rising lifestyle-related stress, the rise in chronic conditions, which can lead to the incidence of PE, increases in cancers, especially prostate cancer is fueling the growth of the North American region in the global market. The increased awareness and various public and private sponsored health campaigns will boost the demand for innovative therapeutics in the North America market. The advent of new drugs and increasing availability of OTC drugs will contribute to the growing sales in the North American region. The increasing interest in sexual health and wellness will create lucrative opportunities for leading vendors across the North America region in the global premature ejaculation therapeutics market.
Germany, the UK, France, Italy, and Spain are the primary revenue contributors across the European region in the global market. The high disease prevalence population, improvement in healthcare spending, increase in PE awareness, increase in uptake of PE drugs especially the off-label generic medicines, and low-cost OTC drugs are fueling the demand across the APAC region in the global premature ejaculation therapeutics market.
The key countries profiled in the report are:
Key Vendor Analysis
The global premature ejaculation therapeutics market is fairly fragmented due to the presence of pharma companies and generic manufacturers. The top vendors are offering off-label drugs, generic versions, and OTC topical anesthetic agents to attract the maximum number of consumers in the global market. The exponential growth of the APAC and Latin American region will create lucrative investment opportunities for prominent players in the market. Factors such as access to drugs, high disease awareness, and high affordability will help companies boost revenues in the global premature ejaculation therapeutics market.
The major vendors in the global market are:
- Absorption Pharmaceuticals
- INNOVUS PHARMACEUTICALS
- Plethora Solutions Holdings
Other prominent vendors include Bayer, Eli Lilly and Company, GlaxoSmithKline, Recordati, Royalty Pharma, The Menarini Group, Ixchelsis and NeuroHealing Pharmaceuticals
Key market insights include
- The analysis of global premature ejaculation therapeutics market provides market size and growth rate for the forecast period 2019-2024.
- It offers comprehensive insights into current industry trends, trend forecast, and growth drivers about the global premature ejaculation therapeutics market.
- The report provides the latest analysis of market share, growth drivers, challenges, and investment opportunities.
- It offers a complete overview of market segments and the regional outlook of global premature ejaculation therapeutics market.
- The report offers a detailed overview of the vendor landscape, competitive analysis, and key market strategies to gain competitive advantage.
FILL IN YOUR DETAILS BELOW TO GET FREE SAMPLE OF THIS REPORT
Our reports have been used by over 10K customers, including:
CEO, Co-founder Audink Inc., DBA Audios
The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow.
Senior Product Manager Interstates
I recently purchased a key Arizton Industry Outlook & Forecast in order to better understand growth for specific market segments and the macro environmental factors impacting this growth. I found Arizton’s coverage of the market dynamics and key takeaways to be insightful and valuable. The segmentation breakouts gave me the information I needed to guide strategic considerations.
Manager Market Analyst Power
Generation & Energy Rolls-Royce Power Systems AG
The provided information by Arizton really met my expectations. Especially the deep information about the datacenter ecosystem was very helpful. Furthermore, I absolutely appreciate the optimal service from the key account managers of Arizton. It was always a pleasure working with them.